Thu, August 4, 2022
Wed, August 3, 2022
Tue, August 2, 2022
Mon, August 1, 2022

Terence Flynn Maintained (BPMC) at Strong Buy with Increased Target to $143 on, Aug 3rd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-143-on-aug-3rd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Terence Flynn of Goldman Sachs, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $126 to $143 on, Aug 3rd, 2022.

Terence has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 4 analyists that currently disagree with Terence


  • Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $80 on, Friday, July 8th, 2022
  • Derek Archila of "Wells Fargo" Initiated at Sell and Held Target at $40 on, Monday, June 27th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022

Publication Contributing Sources